Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

Stopped early · Phase 2

Conditions studied: Idiopathic Pulmonary Fibrosis, Hypoxemia

In brief

This is an open label study in which eligible IPF subjects who are using supplemental oxygen at rest will receive GBT440 orally daily.

Key facts

Study ID
NCT02989168
Run by
Global Blood Therapeutics
People needed
14
Starts
2016-11-01
Expected to finish
2017-10-23
Last updated by the study team
2020-08-21

Who can join

Age: 45 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.